重组组织型纤溶酶原激活剂超早期静脉溶栓治疗急性脑梗死的疗效研究  

Study on the Efficacy of Ultra-early Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in the Treatment of Acute Cerebral Infarction

作　　者：王伟松[1] WANG Weisong(Department of Neurology,Pizhou Hospital of Traditional Chinese Medicine,Pizhou 221300,Jiangsu,China)

机构地区：[1]江苏省邳州市中医院神经内科,江苏邳州221300

出　　处：《中外医疗》2024年第17期21-24,共4页China & Foreign Medical Treatment

摘　　要：目的 探究重组组织型纤溶酶原激活剂(Recombinant Tissue Plasminogen Activator,rt-PA)超早期静脉溶栓治疗急性脑梗死的疗效。方法 随机选取2021年1月—2024年1月江苏省邳州市中医院收治的80例急性脑梗死患者为研究对象,以随机数表法分为两组,研究组(40例)实施rt-PA超早期静脉溶栓治疗,对照组(40例)实施常规治疗。比较两组的美国国立卫生研究院卒中量表(National Institute of Health Stroke Scale,NIHSS)评分、Baethel指数、格拉斯哥昏迷评分法(Glasgow Coma Scale,GCS)评分及不良反应发生情况。结果治疗后,研究组的NIHSS评分低于对照组,GCS评分高于对照组,差异有统计学意义(P均<0.05)。治疗24 h和治疗14 d,研究组的Baethel指数高于对照组,差异有统计学意义(P均<0.05)。研究组的不良反应总发生率低于对照组,差异有统计学意义(P<0.05)。结论 使用rt-PA超早期静脉溶栓治疗急性脑梗死能够有效的提高患者的日常生活活动能力和昏迷指数,快速帮助患者溶解血栓,提高治疗的效果,使得患者脑血流快速恢复,减少脑水肿等不良反应的发生。Objective To investigate the efficacy of ultra-early intravenous thrombolysis with recombinant tissue plasminogen activator(rt-PA) in the treatment of acute cerebral infarction.Methods Eighty patients with acute cerebral infarction admitted to Pizhou Hospital of Traditional Chinese Medicine from January 2021 to January 2024 were randomly selected as study objects and divided into two groups by radnom number table method.The study group(40cases) was treated with ultra-early intravenous thrombolysis with rt-PA,and the control group(40 cases) was treated with conventional therapy.The National Institute of Health Stroke Scale(NIHSS),Baethel Index,Glasgow Coma Scale(GCS) and the occurrence of adverse reactions were compared between the two groups.Results After treatment,the NIHSS score of the study group was lower than that of the control group,and the GCS score was higher than that of the control group,and the differences were statistically significant(both P<0.05).At 24 h and 14 d of treatment,the Baethel index of the study group were higher than that of the control group,and the differences were statistically significant(both P<0.05).The total incidence of adverse reactions in the study group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion The use of rt-PA ultra-early intravenous thrombolysis in the treatment of acute cerebral infarction can effectively improve the patients' ability to perform activities of daily living and coma index,quickly help patients to dissolve the thrombus,improve the effect of treatment,make the patients' cerebral blood flow quickly recovered,and reduce the occurrence of cerebral edema and other adverse reactions.

关 键 词：重组组织型纤溶酶原激活剂 超早期静脉溶栓 急性脑梗死 

分 类 号：R4[医药卫生—临床医学]